DB
BMY icon

Dmitry Balyasny’s Bristol-Myers Squibb BMY Stock Holding History

Dmitry Balyasny’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.64M Sell
115,200
-349,400
-75% -$20.1M 0.01% 1244
2026
Q1 		$28.2M Buy
464,600
+382,600
+467% +$22.3M 0.04% 551
2025
Q4 		$4.42M Buy
82,000
+38,900
+90% +$1.87M 0.01% 1461
2025
Q3 		$1.94M Sell
43,100
-27,300
-39% -$1.27M ﹤0.01% 1808
2025
Q2 		$3.26M Sell
70,400
-94,800
-57% -$4.65M ﹤0.01% 1499
2025
Q1 		$10.1M Buy
165,200
+101,100
+158% +$5.89M 0.02% 905
2024
Q4 		$3.63M Buy
64,100
+11,400
+22% +$637K 0.01% 1422
2024
Q3 		$2.73M Buy
+52,700
New +$2.47M ﹤0.01% 1547
2024
Q2 		– Sell
-26,400
Closed -$1.43M – 2603
2024
Q1 		$1.43M Sell
26,400
-7,000
-21% -$357K ﹤0.01% 1657
2023
Q4 		$1.71M Buy
33,400
+10,100
+43% +$530K ﹤0.01% 1501
2023
Q3 		$1.35M Sell
23,300
-16,700
-42% -$1.02M ﹤0.01% 1489
2023
Q2 		$2.56M Hold
40,000
– – 0.01% 1296
2023
Q1 		$2.77M Sell
40,000
-128,400
-76% -$9.06M 0.01% 1332
2022
Q4 		$12.1M Sell
168,400
-330,000
-66% -$24.9M 0.03% 660
2022
Q3 		$35.4M Sell
498,400
-287,300
-37% -$20.8M 0.11% 237
2022
Q2 		$60.5M Buy
785,700
+10,700
+1% +$815K 0.2% 111
2022
Q1 		$56.6M Buy
+775,000
New +$52M 0.18% 113
2021
Q3 		– Sell
-12,800
Closed -$855K – 1959
2021
Q2 		$855K Buy
+12,800
New +$835K ﹤0.01% 1359
2020
Q4 		– Sell
-300,000
Closed -$18.1M – 1341
2020
Q3 		$18.1M Buy
300,000
+100,000
+50% +$6.02M 0.13% 215
2020
Q2 		$11.8M Buy
+200,000
New +$12M 0.1% 301
2018
Q1 		– Sell
-1,022,500
Closed -$62.7M – 1953
2017
Q4 		$62.7M Buy
1,022,500
+622,500
+156% +$38.9M 0.2% 130
2017
Q3 		$25.5M Buy
+400,000
New +$23.4M 0.1% 274
2015
Q1 		– Sell
-46,500
Closed -$2.75M – 947
2014
Q4 		$2.75M Buy
+46,500
New +$2.62M 0.03% 523

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dmitry Balyasny's BMY Position: Q2 2026 in Review

Dmitry Balyasny reduced its Bristol-Myers Squibb (BMY) stake by 26% in Q2 2026, selling an estimated $1.75M and leaving 88,288 shares worth $5.09M. The position accounts for 0.01% of the portfolio, ranked #1358.

Dmitry Balyasny first reported a position in BMY in Q1 2015 and has held it in 40 quarters since. The position peaked at $100M in Q4 2016. 2,506 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Dmitry Balyasny held 88,288 shares of Bristol-Myers Squibb worth $5.09M as of Q2 2026.
  • Dmitry Balyasny sold 30,409 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.75M.
  • Bristol-Myers Squibb made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1358 holding.
  • Dmitry Balyasny first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 40 quarters since.
  • Dmitry Balyasny's Bristol-Myers Squibb position peaked at $100M in Q4 2016.
  • 2,506 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.